Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage

DOI record: { "DOI": "10.1101/2024.11.11.623127", "URL": "http://dx.doi.org/10.1101/2024.11.11.623127", "abstract": "<jats:p>Pemivibart is a monoclonal antibody therapy currently under Emergency Use Authorization for the for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents over 12 years of age with certain immunocompromised conditions. As a part of the overall monitoring strategy for the activity of pemivibart, the antibody is regularly evaluated against emerging variants of SARS-CoV-2 using pseudovirus neutralization assays. Recent clinical data from Invivyd demonstrates that the PhenoSense pseudovirus assays carried out at Monogram Biosciences have been a reliable and consistent predictor of continued pemivibart clinical activity against SARS-COV-2 variants that have predominated across the timespan that includes the CANOPY clinical trial and the post-EUA authorization period. Additionally, new potential antibodies based upon the structural framework of pemivibart are continuously under evaluation. Fifteen of these yeast-produced pemivibart-like antibodies were tested for neutralization activity against recent variants KP.3 and KP.3.1.1. Like pemivibart, all 15 maintained activity against KP.3.1.1, with the change in IC50 averaging 2.51-fold +/- 0.7 compared to KP.3. Four pemivibart-like antibodies were also tested against the XEC variant, with the change in IC50 averaging 3.01-fold compared to KP.3. These data suggest continued activity for pemivibart and pemivibart-like antibodies against KP.3.1.1 and XEC, recent variants containing N-terminal domain modifications.</jats:p>", "accepted": { "date-parts": [ [ 2024, 11, 13 ] ] }, "author": [ { "affiliation": [], "family": "Powers", "given": "Colin", "sequence": "first" }, { "affiliation": [], "family": "Williams", "given": "Braedon", "sequence": "additional" }, { "affiliation": [], "family": "Kreher", "given": "Alex", "sequence": "additional" }, { "affiliation": [], "family": "Gao", "given": "Feng", "sequence": "additional" }, { "affiliation": [], "family": "West", "given": "Brandyn", "sequence": "additional" }, { "affiliation": [], "family": "Chupp", "given": "Daniel", "sequence": "additional" }, { "affiliation": [], "family": "Allen", "given": "Robert", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2024, 11, 14 ] ], "date-time": "2024-11-14T02:55:14Z", "timestamp": 1731552914000 }, "deposited": { "date-parts": [ [ 2024, 11, 14 ] ], "date-time": "2024-11-14T02:55:14Z", "timestamp": 1731552914000 }, "group-title": "Microbiology", "indexed": { "date-parts": [ [ 2024, 11, 14 ] ], "date-time": "2024-11-14T05:30:49Z", "timestamp": 1731562249498, "version": "3.28.0" }, "institution": [ { "name": "bioRxiv" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 11, 13 ] ] }, "license": [ { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 11, 13 ] ], "date-time": "2024-11-13T00:00:00Z", "timestamp": 1731456000000 } } ], "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2024.11.11.623127", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2024, 11, 13 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2024, 11, 13 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": "http://biorxiv.org/lookup/doi/10.1101/2024.11.11.623127" } }, "score": 1, "short-container-title": [], "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "subtype": "preprint", "title": [ "Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage" ], "type": "posted-content" }